

Express Mail Label Number:

EL514040697US

Please type a plus sign (+) inside this box →



RECEIVED
MAR 22 2002
TECH CENTER 600/2100
PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/028,547		
		Filing Date	December 19, 2001		
		First Named Inventor	Kranzler		
		Group Art Unit	1614		
		Examiner Name	Not yet assigned		
Sheet	1	of	2	Attorney Docket Number	CYPR-023/01US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
W	P1	5,621,142		Mochizuki et al	04-15-1997
W	P2	4,478,836		Mouzin et al	10-23-1984
W	P3	5,034,541		Bigg et al	07-23-1991

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
W	F1		WO 01/26623		Laxdale Limited	04-19-2001	
W	F2		WO 95/22521		Asahi Kasei Kogyo Kabushiki Kaisha	08-24-1995	
W	F3		WO 97/35574		Pierre Fabre Medicament	10-02-1997	
W	F4		WO 98/08495		Pierre Fabre Medicament	03-05-1998	
W	F5		WO 98/36744		Pierre Fabre Medicament	08-27-1998	

Examiner Signature	R. Coth	Date Considered	8/22/02
--------------------	---------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →



RECEIVED
MAR 22 2002
TECH CENTER 1500/2000
PTO/SB/08A (08-00)

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	10/028,547
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 19, 2001
		First Named Inventor	Kranzler
		Group Art Unit	1614
		Examiner Name	Not yet assigned
Sheet	2	of	2
		Attorney Docket Number	CYPR-023/01US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
u	D1	Cypress Bioscience, Inc., Investor Fact Sheet, August 2001	
	D2	DRYSON E., Venlafaxine and fibromyalgia, <i>NZ Med J.</i> , March 10, 2000, 87, 113(1105)	
	D3	NOGUCHI et al., Open Channel Block of NMDA Receptors by Conformationally Restricted Analogs of Milnacipran and Their Protective Effect Against NMDA-Induced Neurotoxicity, <i>Synapse</i> , 1999, 87-96, 31	
	D4	SHUTO et al., (±)-(Z)-2-(Aminomethyl)-1-phenylcyclopropanecarboximide Derivatives as a New Prototype of NMDA Receptor Antagonists, <i>J. Med. Chem.</i> , 1995, 2964-2968, 38	
	D5	SHUTO et al., Synthesis and Biological Activity of Conformationally Restricted Analogs of Milnacipran: (1S,2R)-1-(Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an Efficient Noncompetitive N-Methyl-D-aspartic Acid Receptor Antagonist, <i>J. Med. Chem.</i> , 1996, 4844-4852, 39	
	D6	SHUTO et al., Synthesis and Biological Activity of Conformationally Restricted Analogues of Milnacipran: (1S,2R)-1-Phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboximide Is a Novel Class of NMDA Receptor Channel-Blocker, <i>J. Med. Chem.</i> , 1998, 3507-3514, 41	
n	D7	SHUTO et al., (1S,2R)-1-(Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a New Class of NMDA-Receptor Antagonist: Molecular Design by a Novel Conformational Restriction Strategy, <i>Jpn. J. Pharmacol.</i> , 2001, 207-213, 85	

Examiner Signature	<i>Reusch</i>	Date Considered	8/22/02
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.

Please type a plus sign (+) inside this box →



RECEIVED

MAY 30 2002

#7

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/028,547
				Filing Date	December 19, 2001
				First Named Inventor	Jay D. Kranzler
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	CYPR-023/01US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
N	D8	ARDID, et al., "Antidepressants and pain," <i>La Lettre de Pharmacologue</i> , 13:8, October 1993, 191-195.	
N	D9	NAGAOKA, et al., "Beneficial Effects of a Serotonin-Noradrenaline Reuptake Inhibitor on Fibromyalgia Syndrome: A Case Report," <i>Medicine and Drug Journal</i> , 37:10, October 1, 2001, 238-240.	

Examiner Signature	<i>R. Cook</i>	Date Considered	8/22/02
-----------------------	----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.